Please use this identifier to cite or link to this item:
|Title:||Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer-time for a rethink?|
|Authors:||Cabarkapa, Sonja;Perera, Marlon;Sikaris, Ken;O'Brien, Jonathan S;Bolton, Damien M;Lawrentschuk, Nathan L|
|Affiliation:||Department of Surgery, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia|
Department of Pathology, University of Melbourne, Melbourne, Australia..
Olivia Newton-John Cancer Research Institute, Austin Hospital, Melbourne, Australia
Department of Surgical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Australia
|Citation:||Prostate international 2018; 6(1): 1-6|
|Abstract:||This study aims to review current laboratory reporting strategies across Australia and New Zealand with a view to propose a more useful template for reporting serum testosterone in the context of prostate cancer. Registered pathology laboratories in Australia and New Zealand were enrolled into the current study. An electronic or a phone survey was utilized to collect data from each participating laboratory. Obtained information included assay utilized, units reported, reference intervals, lowest reported value, and lowest detectable value. To identify recommendations for testosterone testing, a systematic search was performed across Web of Science (including MEDLINE), EMBASE, and Cochrane libraries. Assessment of national pathology laboratories identified significant heterogeneity in the reporting methods. Reports typically used a "normal healthy male of 35 years of age" as a comparator but did not refer to optimal castrate levels, the lowest level that their assay was able to detect, nor did they include appended clinical guidelines relating to the prostate cancer patient cohort. Across Australia and New Zealand, various methods for testing and reporting serum testosterone exist, while international guidelines remain vague. The fashion in which serum testosterone levels are displayed should be re-evaluated to address the relevant clinical population and reflect an agreed-upon castrate threshold in patients undergoing androgen deprivation therapy.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.